Safety pharmacology screening: Practical problems in drug development

被引:3
|
作者
Mortin, LI
Horvath, CJ
Wyand, MS
机构
[1] Dept. of Exp. Medicine and Surgery, GTC/TSI Mason Laboratories, Worcester, MA
[2] Dept. of Exp. Medicine and Surgery, T.S.I. Mason Laboratories, Worcester, MA 01608
关键词
cardiovascular; central nervous system; disease models; drug development; general pharmacology; gastrointestinal; safety pharmacology;
D O I
10.1080/109158197227350
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Undesired pharmacologic activities of novel drugs or biologics may limit development of a therapeutic prior to the characterization of any toxicologic effects. In rodent species, general pharmacology assays have traditionally been used to screen new agents for pharmacologic effects on the central and peripheral nervous systems, the autonomic nervous system and smooth muscles, the respiratory and cardiovascular systems, the digestive system, and the physiologic mechanisms of water and electrolyte balance. In large animal species, such as dogs and nonhuman primates, smaller numbers of animals per study limit their we for screening assays, but these species may play an important role in. more detailed mechanistic studies. For drugs and biologics that must be tested in. nonhuman primates because of species-specific action of the test agent, functional pharmacologic data are often collected during acute or subacute toxicity studies. This requires careful experimental design to minimize any impact pharmacologic effects or instrumentation may have on the assessment of toxicity. In addition, with many new therapies targeted at immunologic diseases, the pharmacologic effect of therapeutics on the immune system presents new challenges for pharmacologic profiling. The application of pharmacology assays by organ system in both rodent and large animal species are discussed, as well as practical issues in assessing pharmacology endpoints in the context of toxicity studies.
引用
收藏
页码:41 / 65
页数:25
相关论文
共 50 条
  • [31] Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review
    Boudou-Rouquette, Pascaline
    Tlemsani, Camille
    Blanchet, Benoit
    Huillard, Olivier
    Jouinot, Anne
    Arrondeau, Jennifer
    Thomas-Schoemann, Audrey
    Vidal, Michel
    Alexandre, Jerome
    Goldwasser, Francois
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (12) : 1433 - 1444
  • [32] Core battery safety pharmacology testing-An assessment of its utility in early drug development
    Baldrick, Paul
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 109
  • [33] PRACTICAL ASPECTS OF THE PHARMACOLOGY OF ANTIMICROBIAL DRUG RESIDUES IN FOOD ANIMALS
    RIVIERE, JE
    AGRI-PRACTICE, 1992, 13 (06): : 11 - 16
  • [34] PRACTICAL PHARMACOLOGY FOR OLDER PATIENTS - AVOIDING ADVERSE DRUG EFFECTS
    AHRONHEIM, J
    MOUNT SINAI JOURNAL OF MEDICINE, 1993, 60 (06): : 497 - 501
  • [35] Developing drug prototypes: pharmacology replaces safety and tolerability?
    Cohen, Adam F.
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) : 856 - 865
  • [36] Developing drug prototypes: pharmacology replaces safety and tolerability?
    Adam F. Cohen
    Nature Reviews Drug Discovery, 2010, 9 : 856 - 865
  • [37] Systems pharmacology modeling: an approach to improving drug safety
    Bai, Jane P. F.
    Fontana, Robert J.
    Price, Nathan D.
    Sangar, Vineet
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (01) : 1 - 14
  • [38] Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction
    Puranik, Amrutesh S.
    Halade, Ganesh
    Kumar, Sandeep
    Mogre, Ranjan
    Apte, Kishori
    Vaidya, Ashok D. B.
    Patwardhan, Bhushan
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2011, 2011 : 1 - 8
  • [39] Development of predictive inotropy in silico cardiac safety assay for drug candidate screening
    Maddock, Helen
    Linekar, Adam
    Hurst, Josh
    Wallis, Rob
    Scoffin, Rob
    Slater, Martin
    Kidley, Nathan
    Loeffler, Hannes
    Valentin, Jean-Pierre
    Delaunois, Annie
    Billson, Jeremy
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
  • [40] Urine drug screening: Practical guide for clinicians
    Moeller, Karen E.
    Lee, Kelly C.
    Kissack, Julie C.
    MAYO CLINIC PROCEEDINGS, 2008, 83 (01) : 66 - 76